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Abstract
Shiga toxins (Stxs) are involved in the development of severe systemic complications associated with enterohemorrhagic
Escherichia coli (EHEC) infection. Various neutralizing agents against Stxs are under investigation for management of EHEC
infection. In this study, we immunized chickens with formalin-inactivated Stx-1 or Stx-2, and obtained immunoglobulin Y
(IgY) from the egg yolk. Anti-Stx-1 IgY and anti-Stx-2 IgY recognized the corresponding Stx A subunit and polymeric but not
monomeric B subunit. Anti-Stx-1 IgY and anti-Stx-2 IgY suppressed the cytotoxicity of Stx-1 and Stx-2 to HeLa 229 cells,
without cross-suppressive activity. The suppressive activity of these IgY was abrogated by pre-incubation with the
corresponding recombinant B subunit, which suggests that the antibodies directed to the polymeric B subunits were
predominantly involved in the suppression. In vivo, the intraperitoneal or intravenous administration of these IgY rescued
mice from death caused by intraperitoneal injection of the corresponding toxin at a lethal dose. Moreover, oral
administration of anti-Stx-2 IgY reduced the mortality of mice infected intestinally with EHEC O157:H7. Our results therefore
suggest that anti-Stx IgY antibodies may be considered as preventive agents for Stx-mediated diseases in EHEC infection.
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Introduction
Enterohemorrhagic Escherichia coli (EHEC) causes a spectrum of
human diseases, including diarrhea, hemorrhagic colitis, disor-
dered consciousness, renal failure and hemolytic uremic syndrome
(HUS) [1,2]. EHEC colonizes the large intestine and produces
Shiga toxins (Stxs) as major virulence factors that are involved in
the pathogenicity of EHEC infections. EHEC produces two types
of Stxs, Stx-1 and Stx-2. Stxs released into the intestinal lumen
enter the systemic circulation and reach target organs, where they
manifest their toxicity [3,4]. Stxs are multimeric proteins that
consist of an A subunit (32 kDa) and a pentamer of identical B
subunits (7.7 kDa each). The A subunit links non-covalently to the
pentamer of B subunits. The B pentamer is responsible for the
toxin binding to target cell-surface glycolipid receptors such as
galabiosyl ceramide (Gb2-Cer) and globotriaosyl ceramide (Gb3-
Cer) [5,6]. After binding, the toxin is internalized into the cells,
and the A subunit is cleaved into A1 (28 kDa) and A2 (4 kDa)
fragments. The A1 fragment exerts RNA N-glycosidase activity,
which results in inhibition of protein synthesis by inactivation of
28S rRNA [7,8].
The treatment of EHEC infection with antibiotics is contro-
versial because of the increased risk of HUS owing to
enhancement of Stx induction/release [9]. It has been reported
that some antibiotics markedly enhance Stx-2 production from
EHEC by inducing Stx-encoding bacteriophages [10], and release
Stx-1 that is stored in the periplasm of EHEC in large amounts
[11]. Based on these findings, alternative methods for therapy or
prevention of Stx-mediated diseases have been investigated
worldwide.
Various synthetic compounds that mimic natural receptors,
Gb2-Cer or Gb3-Cer, have been studied for eliminating Stxs from
the intestine by binding to and/or neutralizing Stxs in the
circulation as a therapeutic strategy for protecting patients from
serious Stx-mediated diseases [12–18]. Clinically, Stx-2 is more
potent in the development of Stx-mediated diseases than Stx-1
[19,20]. In mice, the lethal dose of Stx-2 is 400 times lower
compared with Stx-1 [21]. In contrast, it has been shown that the
affinity of Stx-1 for the glycolipid receptor is higher than that of
Stx-2 [22,23]. Therefore, the Gb2-o rG b 3-conjugated compounds
that have been reported as drug candidates show a good
neutralizing activity against Stx-1, but are less active against Stx-
2, although we recently reported that Gb2/Gb3-conjugated to
phosphatidyl residues is relatively effective at neutralizing Stx-2
[18]. Importantly, it has been speculated that the low affinity of
Stx-2 for the receptor might be involved in the higher toxicity in
vivo [22]. A potential approach for the treatment of Stx-mediated
diseases may therefore be the development of agents that bind Stx-
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its natural receptor.
Beside the development of compounds that mimic Stx-2
receptors, monoclonal antibodies against Stxs have also been
investigated for the prevention of Stx-mediated diseases [24–27].
Compared with the synthetic compounds, antibodies are expected
to neutralize Stx-2 effectively, owing to a different neutralizing
mechanism. Antibodies have substantially higher molecular weight
than the intact toxin. The antibodies might interfere with the
binding of Stx to the receptor through steric hindrance and
probably structural instability, regardless of the epitope recog-
nized. This is vastly different from the inhibition mechanism of the
synthetic compounds that are required to bind to the B subunit
binding site. Antibodies are usually administered systemically
through parenteral routes. However, EHEC produces Stx in the
intestine, from where the toxin enters the bloodstream to reach the
target organ [3,4]. While we believe that neutralization of Stxs in
the intestine by oral treatment is more desirable than neutraliza-
tion in the vessel by i.v. treatment for preventing Stx-mediated
diseases, oral administration requires greater quantities of
antibodies compared with parenteral administration.
Recently, there has been increasing interest in the oral
administration of antibodies for localized treatment of gastrointes-
tinal infections [28]. Chicken egg yolk has been recognized as an
economical source of polyclonal antibody for oral administration
[29], and egg yolk immunoglobulin Y (IgY) of chickens immunized
with pathogenic microbes has been extensively studied for the
treatment of various gastroenteric infectious diseases [30–34].
In the present study, we focused on IgY antibodies against Stxs
for oral use to prevent Stx-mediated diseases. Previous investiga-
tions using monoclonal and polyclonal antibodies against Stxs
demonstrated that anti-Stx-1 antibodies do not cross-neutralize
Stx-2, and anti-Stx-2 antibodies do not neutralize Stx-1 [35,36],
although the A subunits of Stx-1 and Stx-2 have 55% and B
subunits of Stx-1 and Stx-2 have 57% deduced amino acid
sequence homology [37]. We therefore immunized chickens with
formalin-inactivated Stx-1 and Stx-2 individually, and character-
ized the obtained IgY preparations for antibody activity that may
potentially allow the prevention of Stx-mediated diseases.
Results
IgY preparation of chicken immunized with partially
purified Stx-1 and Stx-2
Stx-1 and Stx-2 were prepared using bacterial strains (Table 1),
and partially purified preparations (ppStx-1 and ppStx-2) were
used for immunization of chickens, as described in the Materials
and Methods. Fifty-three eggs were collected from chickens
immunized with Stx-1, and 50 eggs from Stx-2-immunized
chickens. Egg yolks were pooled, purified by ammonium sulfate
precipitation and finally freeze-dried. Preparations from Stx-1-
and Stx-2-immunized chickens are referred to as anti-Stx-1 IgY
and anti-Stx-2 IgY, respectively (Table 2).
Western blotting and dot blot analysis of anti-Stx-1 IgY
and anti-Stx-2 IgY
We initially assessed the specificity of anti-Stx-1 IgY and anti-
Stx-2 IgY by western blotting. Highly purified Stx-1 (hpStx-1) and
Stx-2 (hpStx-2) were subjected to SDS-PAGE (Table 1 for
bacterial strains used for toxin preparation). Coomassie Brilliant
Blue (CBB) staining of SDS-PAGE gels loaded with hpStx-1
revealed bands at 32.2 kDa and 6.1 kDa, indicating the Stx-1 A
subunit and monomeric B subunit, respectively. The staining
intensity of the B subunit was stronger than the A subunit
(Figure 1A). For hpStx-2, bands at 33.1 kDa and 8.8 kDa
indicated the Stx-2 A subunit and monomeric B subunit,
respectively. Similarly to hpStx-1, the staining intensity of the B
subunit was stronger than the A subunit. Bands of hpStx-1 and
hpStx-2 at 28.6 kDa most likely represent A1 fragments. The
staining intensity of the Stx-1 A1 fragment was stronger compared
with that of the Stx-1 A subunit. In contrast, the staining intensity
of the Stx-2 A1 fragment was weaker than that of the Stx-2 A
subunit. Western blots of these samples were then probed with
anti-Stx-1 IgY and anti-Stx-2 IgY (Figure 1B, C). Anti-Stx-1 IgY
produced clear bands at the expected positions of the Stx-1 A
subunit and the A1 fragment, compared with Stx-2 (Figure 1B). In
contrast, anti-Stx-2 IgY produced clear bands at the expected
positions of the Stx-2 A subunit and the A1 fragment, compared
with Stx-1 (Figure 1C). Anti-Stx-1 IgY and anti-Stx-2 IgY
Table 1. EHEC or E. coli strains used in this study.
Used for toxin preparation
Strain
a Producing Purification Referred as Used in
GPU96MM Stx-1 and Stx-2
BL21/pETSTX1 Recombinant Stx-1 partially ppStx-1
b Tables 3 and 4, Figure 5
highly hpStx-1 Figures 1–4
GPU993 Stx-2 partially ppStx-2
c Tables 3 and 4, Figure 5
highly hpStx-2 Figures 1–4
JM109/p2Ais-10 Hybrid toxin of Stx-2 A subunit
and Stx-1 B subunit
highly hpStx-2A1B Figure 2
Used for infection experiments
Streptomycin resistant strain Producing Original strain Used in
GPU96MM-S Stx-1 and Stx-2 GPU96MM Figure 6
GPU993-S Stx-2 GPU993
asee ‘‘bacterial strains’’ in Materials and Methods for detail.
bppStx-1 and
cppStx-2 were used for in vivo experiments that required a large amount of Stxs.
doi:10.1371/journal.pone.0026526.t001
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Stx-2 B subunits, respectively (Figure 1B, C).
We further assessed the specificity of anti-Stx-1 IgY and anti-
Stx-2 IgY by dot blot analysis. As shown in Figure 1D, anti-Stx-1
IgY reacted strongly with hpStx-1 and recombinant Stx-1 B
subunit tagged with histidine (Stx-1BH), but weakly with hpStx-2
and recombinant Stx-2 B subunit tagged with histidine (Stx-2BH).
Similarly, anti-Stx-2 IgY reacted strongly with hpStx-2 and Stx2-
BH, but weakly with hpStx-1 and Stx-1BH (Figure 1E).
Neutralizing activity of anti-Stx-1 IgY and anti-Stx-2 IgY
against Stx
The neutralizing activity of the IgY was assessed against five
times the 50% cytotoxic dose (CD50) of hpStx-1, hpStx-2 and
purified hybrid toxin composed of A subunit of Stx-2 and B
subunit of Stx-1 (hpStx-2A1B) (Figure 2). IgY was preincubated
with the different Stx preparations and subsequently subjected to
the cytotoxicity assay. Anti-Stx-1 IgY neutralized hpStx-1 in a
concentration-dependent manner, with a 50% neutralizing
concentration (NC50) of 3.4 mg/ml (95% confidence interval
(CI): 2.5–4.5 mg/ml), while anti-Stx-2 IgY had no effect, even at
the highest concentration of 1000 mg/ml (Figure 2A). Similarly,
anti-Stx-2 IgY neutralized hpStx-2 with an NC50 of 4.8 mg/ml
(95% CI: 4.2–5.5 mg/ml), while anti-Stx-1 IgY had no effect
(Figure 2B). Anti-Stx-1 IgY and anti-Stx-2 IgY neutralized hpStx-
2A1B with an NC50 of 2.7 mg/ml (95% CI: 2.4–3.1 mg/ml),
and 113.3 mg/ml (95% CI: 73.4–174.9 mg/ml), respectively
(Figure 2C). The neutralizing activity of anti-Stx-1 IgY was
similar for hpStx-2A1B and hpStx-1. Anti-Stx-2 IgY, however, did
not show complete neutralization, even at 1000 mg/ml.
Table 2. Anti-Stx-1 IgY and anti-Stx-2 IgY preparations.
Anti-Stx-1 IgY Anti-Stx-2 IgY
Number of eggs 53 50
Total yolk weight (g) 924 846
Freeze-dried powder (g) 8.2 8.6
Protein concentration (g/g powder)
a 0.930 0.970
IgY concentration (g/g protein)
b 0.148 0.230
aassayed using DC
TM Protein assay (BioRad, Hercules, CA, USA).
bassayed using Chicken IgG ELISA Quantitation Kit
TM (Bethyl Laboratories, Inc.,
Montgomery, TX, USA).
doi:10.1371/journal.pone.0026526.t002
Figure 1. Western blot analysis and dot blot analysis. (A–C) Western blot analysis of anti-Stx-1 IgY and anti-Stx-2 IgY. hpStx-1 and hpStx-2 were
subjected to SDS-PAGE at 2.5 mg/lane. (A) CBB staining of SDS-PAGE gel. (B) Anti-Stx-1 IgY and (C) anti-Stx-2 IgY were applied to the membrane at
20 mg/ml. The marks in the figures indicate A subunit, A1 fragment and monomeric B subunit. (D, E) Dot blot analysis of anti-Stx-1 IgY and anti-Stx-2
IgY. hpStx-1 and hpStx-2 were blotted at 4 mg/dot, and Stx-1BH and Stx-2BH at 2 mg/dot. Anti-Stx-1 IgY and anti-Stx-2 IgY were applied to the
membrane at 2 mg/ml and 4 mg/ml, respectively.
doi:10.1371/journal.pone.0026526.g001
IgY for Prevention of Stx-Mediated Diseases
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26526Effect of Stx-1BH and Stx-2BH on the neutralizing activity
of anti-Stx-1 IgY and anti-Stx-2 IgY against Stx
The neutralizing activity of anti-Stx-1 IgY and anti-Stx-2 IgY
were assessed after preincubation with Stx-1BH and/or Stx-2BH.
Stx-1BH decreased the neutralizing activity of anti-Stx-1 IgY
against hpStx-1 in a concentration-dependent manner (Figure 3A),
while Stx-2BH had no effect, even at the highest concentration
(Figure 3B). On the contrary, Stx-2BH, but not Stx-1BH,
decreased the activity of anti-Stx-2 IgY against hpStx-2 in a
concentration-dependent manner (Figure 3C, D).
Neutralizing activity of anti-Stx-1 IgY and anti-Stx-2 IgY
on Stx-1 and Stx-2 bound to target cells
hpStx-1 and hpStx-2 were loaded on to HeLa 229 cells in a
pulsing manner, as described in the legend for Figure 4. The
pulsing of cells with hpStx-1 and hpStx-2 alone (control) showed
52% and 59% cytotoxicity, respectively (Figure 4A, C). When
anti-Stx-1 IgY and anti-Stx-2 IgY were added to the pulsed cells,
only partial neutralization of the toxins was detected, even at the
highest concentration of 1000 mg/ml. On the other hand, when
anti-Stx-1 IgY and anti-Stx-2 IgY were added to the cells before
hpStx-1 and hpStx-2 loading, efficient neutralization of the toxins
was measured, with NC50 values of 5.2 mg/ml (95% CI: 2.8–
9.7 mg/ml) and 2.1 mg/ml (95% CI: 0.9–4.9 mg/ml), respectively
(Figure 4B, D).
Effect of anti-Stx-1 IgY and anti-Stx-2 IgY on mortality of
mice challenged i.p. with a lethal dose of Stx-1 and Stx-2
ppStx-1 and ppStx-2 were used for the mortality assay. After i.p.
challenge with 2.5 times 50% lethal dose (LD50) ppStx-1 and two
times LD50 ppStx-2, five out of six mice died by day 5 in the
control group (Table 3). When anti-Stx-1 IgY was given i.p. at a
dose of 100 mg/kg, 10 min before challenge with ppStx-1, none of
the six mice died. After treatment with 10 mg/kg anti-Stx-2 IgY,
two out of six mice challenged with ppStx-2 died, but at doses of
25 and 100 mg/kg, no mice died.
The protective efficacy was evaluated by i.v. injection of anti-
Stx-1 IgY and anti-Stx-2 IgY (Figure 5). In mice challenged i.p.
with ppStx-1 (Figure 5A), five out of six died in the control group.
However, none of six mice treated with 50 or 100 mg/kg anti-Stx-
1 IgY died. In contrast, all six mice treated with 50 mg/kg anti-
Stx-2 IgY died, and five out of six mice treated with 100 mg/kg
died. In mice challenged i.p. with ppStx-2 (Figure 5B), four out of
six mice died in the control group. In mice treated with 50 mg/kg
anti-Stx-2 IgY, one out of six died, and none of those treated with
100 mg/kg anti-Stx-2 IgY died. In contrast, five out of six mice
died in each group treated with 50 and 100 mg/kg anti-Stx-1 IgY.
Time dependency of treatment with anti-Stx-1 IgY and anti-
Stx-2 IgY was examined (Table 4). In the control group, five out of
six mice challenged i.p. with ppStx-1 died by day 4. In contrast,
none of six mice died that were treated i.v. with anti-Stx-1 IgY at
10 min before or simultaneously with ppStx-1 challenge. Howev-
er, all six mice died when anti-Stx-1 IgY was given later than
10 min after the challenge. After i.p. challenge with ppStx-2, all six
mice died in the control group, but none died when treated i.v.
with anti-Stx-2 IgY 10 min before or simultaneously with ppStx-2
challenge. However, all mice died when anti-Stx-2 IgY was given
later than 10 min after the challenge.
Effect of anti-Stx-1 IgY and anti-Stx-2 IgY on mortality of
mice infected intestinally with GPU993-S and GPU96MM-S
The effect of anti-Stx-1 IgY and anti-Stx-2 IgY on mortality of
mice with intestinal infection with GPU993-S and GPU96MM-S
(Table 1) was investigated (Figure 6). Mitomycin C (MMC) was
injected i.p. at 18, 21 and 24 h after the bacterial inoculation to
enhance Stx-2 production from the bacteria. IgY was adminis-
tered orally at 16, 19, 22 and 40 h. After infection with GPU993-
S (Figure 6A), three out of six mice in the control group and four
Figure 2. Neutralizing activity of anti-Stx IgY. (A) hpStx-1, (B)
hpStx-2 and (C) hpStx-2A1B were mixed with serial dilutions of anti-Stx-
1 IgY and anti-Stx-2 IgY, and incubated for 1 h at 37uC. The mixture was
subjected to the cytotoxicity assay. Final concentration of hpStx-1,
hpStx-2 and hpStx-2A1B was five times CD50. N: cells not treated with
Stx. C: cells treated with Stx alone (control). Each column represents the
mean 6 SEM of triplicate wells. There was a significant difference at
*p,0.05, **p,0.01 and ***p,0.001 vs. the control (Dunnet’s compar-
ison test).
doi:10.1371/journal.pone.0026526.g002
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none of the six mice treated with any dose of anti-Stx-2 IgY (50,
100 and 200 mg/kg) died. After infection with GPU96MM-S
(Figure 6B), four out of six mice died in the control group.
However, two out of six mice died after treatment with 20 mg/kg
anti-Stx-2 IgY, and none of the six mice treated with 100 mg/kg
anti-Stx-2 IgY.
IgY concentration in feces of mice given anti-Stx-2 IgY
orally
The time course of fecal IgY concentration was monitored in
mice administered 200 mg/kg anti-Stx-2 IgY orally. IgY was
detected in the feces collected at 2 h after administration, and
reached a peak of 1.660.1 mg/g feces at 3 h, and then decreased
to almost half the peak level at 12 h (Figure 7).
Discussion
In this study, we immunized chickens with formalin-inactivated
Stx-1 and Stx-2 and obtained anti-Stx-1 IgY and anti-Stx-2 IgY. It
has been reported that rabbits immunized with Stx-1 or Stx-2 do
not produce cross-neutralizing antibody [36,38,39]. First, we
characterized the reactivity of antibodies in the IgY against Stx-1
and Stx-2. Western blot analysis indicated that the IgY reacted
with the A subunit and A1 fragment of the corresponding toxin,
but did not bind to the monomeric form of the B subunit.
Visualization of the Stx B subunits by CBB staining suggested that
a sufficient amount of antigen was present in the blotted lane for
detection of any antibody reactive against monomeric B subunit.
By using SDS-PAGE, proteins were denatured and B subunits
were converted from a polymeric form to monomers. Subse-
quently, the cross-reactivity of IgY against hpStx-1 and hpStx-2
was examined by dot blot assay. The results suggest that IgY was
poorly cross reactive even when Stx had a native A subunit and
polymeric B subunit. Interestingly, the IgY reacted with the
recombinant B subunit, Stx-1BH and Stx-2BH, that has
previously been reported to be in a polymeric form [40], even
though the IgY did not react with the monomeric B subunit in the
SDS-PAGE immunoblotting assay. These results indicated that
anti-Stx-1 IgY and anti-Stx-2 IgY react with the polymeric form of
the B subunit but not the monomeric form, with almost no cross-
reactivity against the polymeric B subunit.
Figure 3. Effect of Stx B subunit on the neutralizing activity of anti-Stx IgY. (A, B) Anti-Stx-1 IgY and (C, D) anti-Stx-2 IgY were mixed with
serial dilutions of Stx-1BH and Stx-2BH, and incubated for 2 h at 37uC. (A, B) hpStx-1 and (C, D) hpStx-2 were added to the mixture, and incubated at
37uC for a further 1 h. The resultant mixture was subjected to the cytotoxicity assay. Final concentrations of hpStx-1 and hpStx-2 were five times CD50,
and those of anti-Stx-1 IgY and anti-Stx-2 IgY were 10 mg/ml. N: cells not treated with Stx. C: cells treated with Stx alone (control). Hatched column (0):
cells treated with Stx and anti-Stx IgY without B subunit. Each column represents the mean 6 SEM of triplicate wells. There was a significant
difference at *p,0.05, **p,0.01 and ***p,0.001 vs. the hatched column (Dunnet’s comparison test).
doi:10.1371/journal.pone.0026526.g003
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concentration of 20 times CD50, and kept on ice for 30 min. Cells were extensively washed with cold DMEM to remove unbound Stx. (A) Anti-Stx-1 IgY
and (C) anti-Stx-2 IgY were added to the Stx-pulsed cells and the cytotoxicity assay was performed. (B) Anti-Stx-1 IgY and (D) anti-Stx-2 IgY were
added to HeLa 229 cells just before addition of (B) hpStx-1 and (D) hpStx-2 at a concentration of five times CD50, and the cytotoxicity assay was
performed. N: cells not treated with Stx. C: cells treated with Stx alone (control). Each column represents the mean 6 SEM of quadruplicate wells.
There was a significant difference at *p,0.05, **p,0.01 and ***p,0.001 vs. the control (Dunnet’s comparison test).
doi:10.1371/journal.pone.0026526.g004
Table 3. Effect of anti-Stx-1 IgY and anti-Stx-2 IgY on mortality of mice challenged with ppStx-1 and ppStx-2.
ppStx-1 ppStx-2
Anti-Stx-1 IgY (mg/kg) Number of mice (Dead/Total) Anti-Stx-2 IgY (mg/kg) Number of mice (Dead/Total)
Control 5/6 Control 5/6
2.5 6/6 2.5 6/6
10 6/6 10 2/6
25 6/6 25 0/6***
100 0/6*** 100 0/6***
ddY mice were administered i.p. with anti-Stx-1 IgY or anti-Stx-2 IgY, followed 10 min later by an i.p. challenge with ppStx-1 (2.5 times LD50) or ppStx-2 (2 times LD50).
Death of mice was observed for 10 days after the challenges.
***There is a statistical significant difference at p,0.001 vs. the control (log rank test).
doi:10.1371/journal.pone.0026526.t003
IgY for Prevention of Stx-Mediated Diseases
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26526Neutralizing activity of anti-Stx-1 IgY and anti-Stx-2 IgY on
Stx-1 and Stx-2 cytotoxicity in HeLa 229 cells was studied. Similar
levels of Stx-1 and Stx-2 were required to induce cytotoxicity in
HeLa 229 cells, which is in agreement with several reports [41–
44]. However, there are also reports showing that Stx-1 is more
toxic than Stx-2 [45,46]. This discrepancy may be attributable to
the number and type of glycolipid receptors present on the cells
used in the experiments. The results indicated that there was no
cross-neutralizing activity of anti-Stx-1 IgY and anti-Stx-2 IgY, as
reported previously in rabbits [36,38,39]. To establish which of the
antibodies against the Stx A subunit or polymeric B subunit
contributes to neutralization of cytotoxicity, neutralizing activity of
anti-Stx-1 IgY and anti-Stx-2 IgY was examined on Stx-2A1B.
Anti-Stx-1 IgY neutralized Stx-2A1B efficiently but anti-Stx-2 IgY
did not. In addition, the neutralizing activity of anti-Stx-1 IgY was
suppressed by Stx-1BH but not Stx-2BH, and the activity of anti-
Stx-2 IgY was suppressed by Stx-2BH but not Stx-1BH. These
findings suggest that the antibody against the polymeric form of B
subunit plays a major role in neutralizing cytotoxicity rather than
the A subunit antibody against A subunit, although there is a
report that mouse monoclonal antibodies against Stx-2 A subunit
neutralize Stx-2 [27]. Moreover, anti-Stx-1 IgY and anti-Stx-2 IgY
did not inhibit the cytotoxicity of bound Stx on the surface of
target cells. Antibodies that recognize the conformational structure
of the polymeric B subunit might inhibit binding of holotoxin
through the B subunit to the receptor, such as Gb3-Cer, to exert
their neutralizing activity. It is recently reported that IgY of
chicken immunized with recombinant Stx-1 B subunit inhibited
the binding of Stx-1 to target cells [47].
The preventive effect of anti-Stx-1 IgY and anti-Stx-2 IgY
against death in mice injected i.p. with a lethal dose of Stx-1 or
Stx-2 was investigated. Less toxicity was reported for Stx-1
compared with Stx-2 in mice [45,48]. Here, ppStx-1 and ppStx-2
were injected i.p. at 625 mg/kg, corresponding to 50 mg/kg Stx-1,
and 17.4 mg/kg corresponding to 1 mg/kg Stx-2, as a potentially
lethal dose for almost all mice within a few days. Anti-Stx-1 IgY
and anti-Stx-2 IgY showed protection following i.v. as well as i.p.
administration in mice challenged i.p. with the corresponding Stx,
without cross-preventive activity in agreement with the results in
vitro. The experiment for time dependency of the treatment
showed that anti-Stx-1 IgY and anti-Stx-2 IgY were effective when
given 10 min before or simultaneously with Stx-1 and Stx-2, but
not when given later than 10 min after Stx injection. Stx can enter
the circulation within a few minutes after i.p. injection, and reach
the target organs. It is reported that 90% of Stx-1 and Stx-2 is
cleared from the blood within 5 min after i.v. injection in mice
[49]. The results suggest that the antibodies in anti-Stx-1 IgY and
anti-Stx-2 IgY cannot inhibit toxicity after binding of the toxins to
target organs. This was supported by the in vitro experiment in
which anti-Stx-1 IgY and anti-Stx-2 IgY did not neutralize Stx
after binding to target cells. From the perspective of preventing
Stx-mediated diseases, Stx should be inactivated in the intestine
before it enters the circulation, rather than in the blood stream.
However, there were reports describing that monoclonal antibody
Figure 5. Effect of anti-Stx IgY given via different routes from Stx on mortality of mice. (A) ppStx-1 (2.5 times LD50) and (B) ppStx-2 (2
times LD50) were administered i.p. to ddY mice. Anti-Stx-1 IgY and anti-Stx-2 IgY were given i.v. at doses of 50 and 100 mg/kg at 10 min before
challenge. Control mice were given PBS instead of anti-Stx IgY. Each group included six mice. There was a significant difference at *p,0.05 and
***p,0.001 vs. the control (log rank test).
doi:10.1371/journal.pone.0026526.g005
Table 4. Mortality of mice administered anti-Stx-1 IgY and
anti-Stx-2 IgY after challenge with ppStx-1 and ppStx-2.
Mortality (Dead/Total)
Anti-Stx-1 IgY Anti-Stx-2 IgY
Timing of IgY
administration (min) ppStx-1 ppStx-2
Control 5/6 6/6
210 0/6*** 0/6***
0 0/6*** 0/6***
10 6/6 6/6
20 6/6 6/6
30 6/6 6/6
60 6/6 6/6
120 6/6 6/6
360 6/6 6/6
ddY mice were challenged i.p. with 2.5 times LD50 ppStx-1 and 2 times LD50
ppStx-2. Anti-Stx-1 IgY and anti-Stx-2 IgY were given to mice i.v. at a dose of
100 mg/kg at various timing on the challenge.
***There is a statistical significant difference at p,0.001 vs. the control (log rank
test).
doi:10.1371/journal.pone.0026526.t004
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intestinally with EHEC even when the antibody was given i.p.
24 to 48 h after the EHEC infection [26,50]. In this case, diarrhea
started after 16 h and neurological symptoms at 48 to 96 h due to
Stx-2 suggesting that Stx entered the bloodstream from the
intestine after this point. The i.p. administration of the monoclonal
antibody at 24 to 48 h may precede entering of Stx to the
bloodstream in this piglet model.
Anti-Stx-1 IgY and anti-Stx-2 IgY wereexamined for oral efficacy
to prevent the death of mice infected intestinally with EHEC
O157:H7. GPU993-S produced only Stx-2, and GPU96MM-S
produced Stx-1 and Stx-2. MMC treatment enhances Stx-2
production of EHEC in the intestine [51]. These experiments were
designed to examine not only if the IgY inactivates Stxs in the
intestine but also the potential of co-administration of the IgY with
antibiotics simulating the likely clinical setting for EHEC
infection, although MMC was used instead of antibiotics. Stx-2
concentration in the cecum increases drastically 3 h after the first
MMC treatment and peaks 6 h after (HM un-published data).
The IgY is expected to reach the colon 2 to 3 h after oral
administration as supported by the data in Figure 7. Then, anti-
Stx-1 IgY and anti-Stx-2 IgY were given orally at the time of
MMC treatment. Anti-Stx-2 IgY protected mice from death
caused by GPU993-S infection, but anti-Stx-1 IgY did not affect
mortality. Anti-Stx-2 IgY also prevented death of mice infected
with GPU96MM-S. It is likely that anti-Stx-2 IgY suppressed
entry of Stx-2 into the circulation, which resulted in prevention of
death. IgY given orally was detected in the feces by a peak
concentration at 3 h after administration. It is expected that oral
IgY reaches the large intestine to express its antibody activity.
The mechanism for Stx to enter the circulation from the intestine
is not precisely known, although there are several reports about
the mechanisms [52–54]. It is still possible that antibody against
Stx A subunit contributes to suppression of Stx entry into the
circulation, while antibody against A subunit is not involved in
neutralization of Stx, as shown in this study. It remains to be
established which antibodies against A subunit and B subunit are
effective for inactivation of Stx in the intestine to elucidate the
precise mechanism for the IgY to inactivate Stx in the intestine.
The oral efficacy of anti-Stx-1 IgY has not yet been determined
in an intestinal infection model in mice, because we have no model
in which Stx-1 is produced in the intestine and causes death. This
also remains to be studied, although Stx-2 is more toxic than Stx-1
in mice [48], and more likely to be involved in the development of
HUS in humans [20,55].
In conclusion, we demonstrated that chickens immunized with
Stx toxoid can produce IgY antibodies that can inactivate Stx in
the intestine. It is possible to obtain IgY from egg yolk in large
amounts at low cost. Anti-Stx-1 IgY and anti-Stx-2 IgY have the
potential to be used clinically for the prevention of Stx-mediated
diseases. It is possible to use oral IgY in combination with
antibiotics to help reduce the risk of Stx-mediated diseases due to
the use of antibiotics.
Figure 6. Effect of orally administered anti-Stx IgY on mortality of mice infected with EHEC O157:H7. (A) GPU993-S and (B) GPU96MM-S
were inoculated intragastrically to Balb/c mice. GPU993-S and GPU96MM-S were resistant to streptomycin. Mice inoculated with these bacteria were
given drinking water supplemented with streptomycin throughout the experimental period. MMC was injected i.p. at 18, 21 and 24 h, and anti-Stx-1
IgY or anti-Stx-2 IgY was given at 16, 19, 22 and 40 h after inoculation. Control mice were given PBS instead of anti-Stx IgY. Each group included 6
mice. There was a significant difference at *p,0.05 vs. the control (log rank test).
doi:10.1371/journal.pone.0026526.g006
Figure 7. Time course of IgY concentration in feces of mice
given anti-Stx-2 IgY orally. ddY mice were given 200 mg/kg anti-
Stx-2 IgY orally. IgY concentration was measured by ELISA. Each point
represents the mean 6 SEM of five mice.
doi:10.1371/journal.pone.0026526.g007
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Bacterial strains
EHEC GPU96MM was a clinical isolate of EHEC O157:H7,
which produced Stx-1 and Stx-2 in the outbreak at Gifu, Japan in
1996 [56]. E. coli BL21/pETSTX1 was a recombinant strain that
produced Stx-1 [17]. E. coli GPU993 was a stx1-deletion mutant of
EHEC GPU96MM that produced Stx-2 [57]. E. coli JM109/
p2Ais-10 [58] was a recombinant strain that produced a hybrid
toxin composed of A subunit of Stx-2 and B subunit of Stx-1 (Stx-
2A1B).
Resistance to streptomycin was spontaneously induced in
GPU96MM and GPU993 by passaging in nutrient broth (Nissui
Pharmaceutical, Tokyo, Japan) that contained 5 mg/ml strepto-
mycin sulfate (Meiji Seika, Tokyo, Japan), and defined as
GPU96MM-S and GPU993-S, respectively, to be used for the
infection experiments.
Experimental animals
Commercially available chickens were maintained under
conventional conditions in the animal room of the Immunology
Research Institute, GHEN Corporation (Gifu, Japan), and
immunized with Stx-1 and Stx-2 at 24 weeks of age. The
experiments were performed in accordance with the Guidance for
the Care and Use of Laboratory Animals of GHEN Corporation
in Nov. 2004. All procedures that involved animals were approved
by the Animal Care and Use Committee of Immunology Research
Institute, GHEN Corporation (approval number 04-1128).
SPF female ddY mice and SPF female Balb/c mice were
obtained at 4 weeks of age from Japan SLC (Hamamatsu, Japan),
and used for the experiments after 1 week acclimation. Mice were
maintained in the Laboratory for Animal Experiments of Gifu
Pharmaceutical University (Gifu, Japan), with free access to
sterilized rodent chow (CRF-1; Oriental Yeast, Tokyo, Japan) and
water. The experimental designs and all procedures were approved
by the Animal Experiment Committee of Gifu Pharmaceutical
University (permission number; 05-130, 05-154, 05-363, 06-082,
and 06-132). All procedures relating to animal care and treatment
conformed to animal care guidelines of this committee.
Partial purification of Stx-1, Stx-2 and Stx-2A1B
E. coli BL21/pETSTX1 was grown at 37uC with shaking in
Luria–Bertani broth supplemented with 60 mg/l ampicillin (Wako
Pure Chemicals Industries, Osaka, Japan) to prepare Stx-1. At the
mid-logarithmic phase, isopropyl b-D(-)- thiogalactopyranoside
(Wako Pure Chemicals Industries) was added at a final concentra-
tion of 1 mM, and the culture was continued for an additional 6 h.
The cell pellet harvested by centrifugation was resuspended in PBS
(pH 7.4) that contained polymyxin B (0.1 mg/ml), incubated at
37uC for 30 min, and then centrifuged. The supernatant was
filtered through a 0.22-mm filter (Millex; Millipore). The filtrate was
then extensively dialyzed and concentrated against PBS using
Stirred Ultrafiltration Cell with a 30 000 molecular weight cut-off
membrane (Amicon; Millipore). The preparation was referred to as
partially purified Stx-1 (ppStx-1). Partially purified Stx-2A1B
(ppStx-2A1B) was prepared from E. coli JM109/p2Ais-10 in the
same method described above for ppStx-1.
E. coli GPU993 was cultured at 37uC with shaking in modified
Syncase medium [17] to prepare Stx-2. At the mid-logarithmic
phase of growth, 0.6 mg/ml MMC (Kyowa Hakko Kogyo, Tokyo,
Japan) was added to the culture to stimulate Stx-2 production,
followed by cultivation for an additional 6 h. The culture
supernatant obtained by centrifugation was concentrated by
ultrafiltration with 30 000 molecular weight cut-off membrane
(Pellicon 2 Cassette filter Biomax 30; Millipore). The filtrate was
extensively dialyzed and concentrated against PBS using Stirred
Ultrafiltration Cell with a 30 000 molecular weight cut-off
membrane (Amicon, Millipore). This preparation was referred to
as partially purified Stx-2 (ppStx-2).
Stx-1 and Stx-2 concentrations and cytotoxic activities were
assayed by ELISA and cytotoxicity assay described below. The
Stx-1 concentration in ppStx-1 was 80.1 mg/mg protein and Stx-2
in ppStx-2 was 57.6 mg /mg protein. The CD50 against HeLa 229
cells was 8.8 pg/ml Stx-1 in ppStx-1 and 1.1 pg/ml Stx-2 in
ppStx-2.
Highly purification of Stx-1, Stx-2 and Stx-2A1B
Stx-1, Stx-2 and Stx-2A1B were highly purified from the
respective partially purified preparations (ppStx-1, ppstx-2 and
ppStx-2A1B) by affinity chromatography using Gb3-Cer (Nacalai
Tesque) as described previously [17,59], and referred to as hpStx-
1, hpStx-2 and hpStx-2A1B, respectively. The CD50 was 9.3 pg/
ml, 1.2 pg/ml and 8.2 pg/ml in hpStx-1, hpStx-2 and hpStx-
2A1B, respectively.
Purification of recombinant B subunit of Stx-1 and Stx-2
Stx-1BH and Stx-2BH were purified by affinity chromatogra-
phy with Ni
2+-loaded HiTrap Chelating HP column (Amersham
Biosciences, Tokyo, Japan) as described previously [40,60], and
referred to as Stx-1BH and Stx-2BH, respectively.
Immunization of chickens with ppStx-1 and ppStx-2
ppStx-1 and ppStx-2 were diluted with PBS, mixed with 0.5%
final concentration formalin, and kept for 3 days at 37uC. The
formalin-inactivated preparations were mixed with an equal
volume of Freund’s complete adjuvant (Difco, Detroit, MI,
USA), and the mixture was injected into two different sites of
the breast muscle (0.5 ml per site, 50 mg Stx-1 or Stx-2/chicken).
One month later, the chickens were boosted by injecting the
inactivated preparation with Freund’s incomplete adjuvant (Difco)
in the same manner (100 mg Stx-1 or Stx-2/chicken). Two
chickens were used for each immunization with Stx-1 and Stx-2.
Purification of anti-Stx-1 and anti-Stx-2 IgY
The eggs were harvested at 2–7 weeks after the booster, and the
yolks were isolated and pooled. The pooled yolk was well mixed
with 10 times volume of distilled water, and kept at 4uC overnight.
Ammonium sulfate was added to the supernatant to bring the
saturation to 40%. The overnight precipitate was dissolved with
40 mM NaCl, and then dialyzed against a sufficient quantity of
40 mM NaCl. The dialyzed solution was freeze-dried.
ELISA to detect Stxs
Stx-1 and Stx-2 concentrations were determined by ELISA [61]
using mouse anti-Stx-1B subunit monoclonal antibody (STX1-
13C4; Toxin Technology, Sarasota, FL, USA) or anti-Stx-2B
subunit monoclonal antibody (STX2-BB12; Toxin Technology) as
a capture antibody, and mouse anti Stx-1 and Stx-2 pooled
antibodies conjugated to horseradish peroxidase (STXPC-1;
Toxin Technology) as a developing antibody. Purified Stx-1 and
Stx-2 purchased from Nacalai Tesque, Inc. (Kyoto, Japan) were
used to prepare the standard curves.
Cytotoxicity assay to detect Stx-neutralizing activity
The cytotoxicity assay was performed as described previously
[17,18]. Briefly, 5610
3/well of HeLa 229 cells (kindly provided by
Dr. T. Yoshida, Aichi Medical University, Aichi Prefecture, Japan)
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(Nissui Pharmaceutical) supplemented with 10% heat-inactivated
fetal bovine serum (ICN Biomedicals, Aurora, OH, USA), 100 U/
ml penicillin G and 0.1 mg/ml streptomycin with 96-well flat
bottomed culture plates (Costar; Corning Inc., Corning, NY,
USA). After 24 h incubation, serial dilutions of hpStx-1 or hpStx-2
were added to the wells. Then, the cultures were continued for
48 h. AlamarBlue (Trek Diagnostic Systems, East Grinstead, West
Sussex, UK) was added to the wells, followed 2 h later by
measuring fluorescence intensity (FI) at 590 nm (530 nm excita-
tion, CytoFluor 2350; Millipore, Bedford, MA, USA) to estimate
the number of viable cells. The CD50 of Stx-1 and Stx-2 was
estimated from the dose–response curves of the serial dilutions.
To evaluate Stx neutralizing activity of anti-Stx-1 and anti-Stx-2
IgY, the appropriately diluted IgY were mixed with five times
CD50 hpStx-1 or five times CD50 hpStx-2, incubated at 37uC for
1 h, and then subjected to the cytotoxicity assay. Neutralizing
concentration of the IgY was calculated as follows and the NC50
was calculated:
NC~FIof IgY{FI of Control ðÞ =FIof Non-treated{FIof Control ðÞ |100:
Western blotting of anti-Stx-1 and anti-Stx-2 IgY
hpStx-1 and hpStx-2 (2.5 mg/lane) were subjected to SDS-
PAGE (15% polyacrylamide gel). The gels were stained with CBB
R-250. For western blotting, proteins were transferred to 0.22-mm
polyvinylidene difluoride membranes (Nippon Genetics, Tokyo,
Japan) with a semi-dry transfer apparatus (BE-330; Bio Craft,
Tokyo, Japan). The membrane was blocked for 1 h with PBS that
contained 1% bovine serum albumin, 5% normal calf serum and
0.1% Tween 20 (BB). Anti-Stx-1 IgY and anti-Stx-2 IgY, diluted
to 20 mg/ml in BB, were applied to the membranes and
incubated for 5 h. The membranes were then incubated for 2 h
with rabbit anti-chicken IgG conjugated to horseradish peroxi-
dase (Zymed, San Francisco, CA, USA) diluted at 1:4000 in BB.
The reaction was visualized by a substrate solution of 0.5 M
Tris–HCl buffer (pH 6.8) that contained 0.2 mg/ml 3, 39-
diaminobenzidine tetrahydrochloride (Wako Pure Chemicals
Industries) and 0.2 ml/ml 30% H2O2.
Dot blot analysis of anti-Stx-1 and anti-Stx-2 IgY
hpStx-1 and hpStx-2 were blotted onto 0.22-mm polyvinylidene
difluoride membranes (Nippon Genetics) at 0.4 mg/10 ml/dot, and
Stx-1BH and Stx-2BH at 2 mg/10 ml/dot. Anti-Stx-1 IgY (2 mg/
ml) and anti-Stx-2 IgY (4 mg/ml) diluted in BB were applied to the
dot and incubated for 5 h. The following procedure to stain was
the same as described for western blotting.
Mouse mortality assay by i.p. challenge with ppStx-1 and
ppStx-2
ddY mice were used for the experiment. The 50% lethal dose
(LD50) of ppStx-1 was 250 mg/kg (20 mg/kg as Stx-1) and that of
ppStx-2 was 8.7 mg/kg (0.5 mg/kg as Stx-2). In the mortality assay
to examine the in vivo neutralizing activity of anti-Stx-1 IgY and
anti-Stx-2 IgY, mice were challenged i.p. with 625 mg/kg ppStx-1
(2.5 times LD50) and/or 17.4 mg /kg ppStx-2 (two times LD50).
Mouse survival was observed for 10 days after the challenge.
Intestinal infection with EHEC O157:H7
The infection experiment with GPU993-S and GPU96MM-S
was performed as described previously [17]. Balb/c mice were
given drinking water supplemented with 5 mg/kg streptomycin,
continuously from 2 days before infection throughout the
experimental period. Mice were starved of food for 8 h and then
injected i.p. with 25 mg/kg cimetidine, followed 15 min later by
intragastric inoculation with 5610
4 cfu/kg GPU993-S or
GPU96MM-S. MMC was injected i.p. at a dose of 0.25 mg/kg
at 18, 21 and 24 h after bacterial inoculation. Mouse survival was
observed for 14 days after the inoculation.
Measurement of IgY concentration in feces
ELISA was used to measure IgY concentration in feces of mice
given anti-Stx-2 IgY orally. Two or more fecal pellets were
collected from the mice, weighed, and suspended in five volumes
of PBS that contained 0.1% sodium azide. The pellets were
crushed by shaking vigorously in a tube that contained glass beads.
The suspension was then centrifuged at 15 000 rpm for 20 min to
obtain a clear supernatant. In the ELISA to measure the IgY
concentration in the supernatant, rabbit anti-chicken IgG (Bethyl,
Montgomery, TX, USA) was used as a capture antibody and
rabbit anti-chicken IgG conjugated to horseradish peroxidase
(Zymed) as a developing antibody. Commercially available
purified chicken IgG (Cappel, Aurora, OH, USA) was used to
make a standard curve. IgY concentration (mg/g feces) was
calculated from the curve using GraphPad PRISM (GraphPad
Software, San Diego, CA, USA).
Statistical analysis
Results are presented as the mean 6 SEM. GraphPad PRISM
(GraphPad Software) was used to calculate CD50 and NC50, and
statistical analyses. Neutralizing activity of IgY preparations was
evaluated by Dunnet’s comparison test after one way analysis of
variance (Figures 2–4). Survival time of mice was evaluated by log
rank test (Tables 3 and 4, Figures 5 and 6). A value of p,0.05 was
considered to be statistically significant in all analyses.
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